We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




LAMP Assay Detects Clonorchiasis in Human Samples

By LabMedica International staff writers
Posted on 26 Oct 2017
Clonorchiasis is prevalent in the Far East, and a major health problem in endemic areas. More...
Infected persons may experience, if not treated, serious complications such as bile stone formation, pyogenic cholangitis, and even cholangiocarcinoma.

The specific diagnosis of Clonorchis sinensis is important for successful treatment and control of the infection. The Kato-Katz (KK) method and/or formalin-ether concentration technique are commonly used for clonorchiasis diagnosis. However, stool examinations are not highly effective because lightly infected cases can be missed.

Scientists at the Seoul National University Medical Research Center (Seoul, Korea) and their colleagues randomly selected from the pool of stool samples of the residents of Sancheong County in Korea, where clonorchiasis is endemic, and risk factors and incidence of cholangiocarcinoma among this resident were investigated since 2006. For each stool sample, two KK smears and one real-time polymerase chain reaction (PCR) were performed. For the KK smear, 41.7 mg of feces was examined by microscopy and multiplied by 24 to convert to eggs per gram of feces (EPG).

A loop-mediated isothermal amplification (LAMP) assay was applied for the detection of Clonorchis sinensis DNA. Six primers targeting eight locations on the cytochrome c oxidase subunit 1 gene of C. sinensis were designed for species-specific amplification using the LAMP assay. Amplified LAMP products were detected directly either by the naked eye or by placing the reaction tube under UV light. In addition, 5.0 μL of the LAMP products was examined by electrophoresis on a 2% agarose gel, followed by ethidium bromide staining and visualization under UV light.

The LAMP assay was sensitive enough to detect as little as 100 fg of C. sinensis genomic DNA and the detection limit in 100 mg of stool was as low as one egg. The assay was highly specific because no cross-reactivity was observed with the DNA of other helminths, protozoa or Escherichia coli. Then, the LAMP assay was applied to human fecal samples collected from an endemic area of clonorchiasis in Korea. Using samples showing consistent results by both Kato-Katz method and real-time PCR as reference standards, the LAMP assay showed 97.1% of sensitivity and 100% of specificity. In stool samples with more than 100 eggs per gram of feces, the sensitivity achieved 100%.

The authors concluded that they had developed a highly sensitive and specific LAMP assay for detection of C. sinensis DNA in human fecal samples. Due to the shorter reaction time and better visual judgment of positivity without requiring sophisticated instruments, the LAMP assay can be more easily applied in field laboratories than PCR as a powerful tool for more specific and reliable diagnosis of clonorchiasis, thereby improving both treatment and control programs. The study was published on October 9, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Seoul National University Medical Research Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.